Lung Cancer (Non-Small Cell) Clinical Trials

23 recruitingLast updated: June 17, 2026

There are 23 actively recruiting lung cancer (non-small cell) clinical trials across 7 countries. Studies span Phase 2, Not Applicable, Phase 1. Top locations include Guangzhou, China, London, United Kingdom, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Lung Cancer (Non-Small Cell) Trials at a Glance

23 actively recruiting trials for lung cancer (non-small cell) are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Guangzhou, London, and Beijing. Lead sponsors running lung cancer (non-small cell) studies include Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Essen Biotech, and Barzilai Medical Center.

Browse lung cancer (non-small cell) trials by phase

Treatments under study

About Lung Cancer (Non-Small Cell) Clinical Trials

Looking for clinical trials for Lung Cancer (Non-Small Cell)? There are currently 23 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Cancer (Non-Small Cell) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Cancer (Non-Small Cell) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Phase 2

A Phase II Study of SKB571 in Patients With Lung Cancer

Lung Cancer (Non-Small Cell)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.295 enrolled2 locationsNCT07230405
Recruiting

Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device

Lung Cancer (Non-Small Cell)
Tianjin Medical University Cancer Institute and Hospital50 enrolled1 locationNCT07561567
Recruiting

Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques

Lung Cancer (Non-Small Cell)
Second Affiliated Hospital, School of Medicine, Zhejiang University450 enrolled3 locationsNCT06687408
Recruiting
Not Applicable

The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer

Lung Cancer (Non-Small Cell)
University of Arizona48 enrolled1 locationNCT07216209
Recruiting

Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery

SarcopeniaLung Cancer (Non-Small Cell)Malnutrition Severe
Ondokuz Mayıs University142 enrolled1 locationNCT07500376
Recruiting
Phase 2

IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Lung Cancer (Non-Small Cell)
Guangdong Association of Clinical Trials48 enrolled7 locationsNCT07198841
Recruiting
Not Applicable

Engagement of Veterans With Lung Cancer

Lung CarcinomaLung Cancer (Non-Small Cell)Lung Adenocarcinoma+3 more
Palo Alto Veterans Institute for Research194 enrolled1 locationNCT07219251
Recruiting
Phase 1Phase 2

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

Breast CancerProstate Cancer Castration-resistant Prostate CancerColo-rectal Cancer+2 more
MBrace Therapeutics150 enrolled7 locationsNCT07145255
Recruiting
Phase 1Phase 2

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer (Non-Small Cell)
GlaxoSmithKline40 enrolled1 locationNCT06405230
Recruiting
Not Applicable

Shared Decision Making on Radiation Dose for Lung Malignancies

Lung Cancer (Non-Small Cell)Radiation ToxicityLung Metastases+2 more
Vejle Hospital40 enrolled1 locationNCT04940936
Recruiting
Phase 1Phase 2

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Advanced CancerLung Cancer (Non-Small Cell)Solid Tumor, Adult+2 more
Krystal Biotech, Inc.250 enrolled14 locationsNCT06228326
Recruiting

Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer

Lung Cancer (Non-Small Cell)Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences500 enrolled1 locationNCT07166003
Recruiting
Phase 2

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

Lung Cancer (Non-Small Cell)
Shanghai Chest Hospital32 enrolled1 locationNCT06659042
Recruiting

Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer

Lung Cancer (Non-Small Cell)
JaxBio Ltd300 enrolled1 locationNCT06963307
Recruiting
Phase 2

Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)

Lung Cancer (Non-Small Cell)
The First Affiliated Hospital of Guangzhou Medical University69 enrolled1 locationNCT06926790
Recruiting

TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO

Lung Cancer (Non-Small Cell)Small Cell Lung CancerPleural Mesothelioma
University College, London600 enrolled1 locationNCT05628376
Recruiting

Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerLung Cancer (Non-Small Cell)+2 more
Barzilai Medical Center10 enrolled1 locationNCT06889467
Recruiting

Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

Lung Cancer (Non-Small Cell)EGFR Exon 19 Deletion Mutation
Our Lady of the Lake Hospital20 enrolled1 locationNCT06659458
Recruiting
Not Applicable

Standard Care With or Without Early Palliative Care Provided by Palliative Care Specialist in Advanced Non-small Cell Lung Cancer Patients

Lung Cancer (Non-Small Cell)Lung Cancer (NSCLC)
Mahidol University104 enrolled1 locationNCT06786468
Recruiting
Phase 2

A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC

Lung Cancer (Non-Small Cell)
Sichuan University28 enrolled1 locationNCT06769295